Main information



  • Available in:
  • Language:
  • English

Other information


  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 217489
  • Last update:
  • 09-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:



ARTG entry for

Medicine Listed


Health World Ltd

Postal Address

PO Box 675,VIRGINIA BC, QLD, 4014


ARTG Start Date


Product category




Approval area

Listed Medicines


Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in

the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be


The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.



Product Type

Single Medicine Product

Effective date



If symptoms persist consult your healthcare practitioner (or words to that effect).

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Specific Indications

Herbs and nutritional support for healthy female reproduction function.To support the female reproductive system in traditional Ayurvedic and Chinese

medicine. Shatavari supports female reproduction in traditional Ayurvedic medicine. Rehmannia assists in regulating menstruation in traditional Chinese

medicine. Dong Quai is used as a female tonic and to support regulation of menstruation in traditional Chinese medicine. Codonopsis is used as a tonic

in traditional Chinese medicine. Vitamin E acts as an antioxidant or a free radical scavenger. Iron is required for oxygen transport in the body. Draws

from traditional Chinese and Ayurvedic medicine. Support for normal healthy female reproductive function. Metagenics Ovarianne has been specifically

formulated to support normal healthy reproductive function in women. It draws on traditional Chinese and Ayurvedic medicine to provide herbs such as

Shatavari, Rehmannia and Dong Quai which have traditionally been used to support the female reproductive system.

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule


1. Formulation 1

Dosage Form

Tablet, film coated

Route of Administration


Visual Identification

Active Ingredients

Angelica polymorpha

180 mg

Equivalent: Angelica polymorpha (Dry)

1.8 g

Public Summary

Page 1 of

Produced at 23.11.2017 at 12:56:14 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit for contact information

Asparagus racemosus

294.118 mg

Equivalent: Asparagus racemosus (Dry)

2.5 g

Codonopsis pilosula

140.625 mg

Equivalent: Codonopsis pilosula (Dry)

1.125 g

d-alpha-Tocopheryl acid succinate

82.8 mg

Iron amino acid chelate

25 mg

Rehmannia glutinosa

150 mg

Equivalent: Rehmannia glutinosa (Dry)

1.5 g

Zingiber officinale

12.5 mg

Equivalent: Zingiber officinale (Dry)

500 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at

Public Summary

Page 2 of

Produced at 23.11.2017 at 12:56:14 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit for contact information